NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs
The National Medical Products Administration (NMPA) today announced the release of its 95th Reference‑Listed Drugs...
NMPA
China’s NMPA Resumes Import of Vasudha’s Loratadine API After Rectifications
China’s National Medical Products Administration (NMPA) announced on August 20, 2025, that it had resumed...
InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors
China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...
NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services
On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...
NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs
On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...
NMPA Updates Review Procedures for Conditional Drug Marketing Approval Applications
The National Medical Products Administration (NMPA) this week released a revised draft proposal for the...
NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...
NMPA Unveils Measures to Support High-End Medical Device Innovation with Full Lifecycle Regulation
China’s National Medical Products Administration (NMPA) last week released the “Measures to Optimize Full-lifecycle Regulation...
NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...
CDE Issues New Requirements for IND Applications of Innovative Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) this week...
NMPA Issues Immediate Guidelines for NGS-Related IVD Reagent Classification
China’s National Medical Products Administration (NMPA) released the “Guidelines for Classification Definition of Next-Generation Sequencing...
China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations
China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...
NMPA Releases Updated List of Medical Devices Exempted from Clinical Evaluation
The National Medical Products Administration (NMPA) has released the latest version of the “List of...
China’s NMPA Releases Draft Guidelines for Development Risk Management Plan
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...
NMPA Issues New Quality Management Standards for Online Medical Device Sales
The National Medical Products Administration (NMPA) has released the “Announcement on Quality Management Standards for...
NMPA Issues 91st Batch of Reference Standards for Generic Drug Quality Evaluation
The National Medical Products Administration (NMPA) has released the 91st batch of reference standards for...
NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes
The National Medical Products Administration (NMPA) has announced new measures to optimize the drug manufacturing...
China Proposes New Measures to Optimize High-End Medical Device Regulation
The National Medical Products Administration (NMPA) has released the “Measures for Optimizing Full Lifecycle Supervision...
China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled
China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...
China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control
China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...